Relay Therapeutics 

Yahoo Finance • last month

Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week

Key Points An analyst initiated coverage of the biotech. Not only does he consider it a buy, he's also designated it as one of his firm's top picks.10 stocks we like better than Relay Therapeutics › Precision medicine specialist Relay Th... Full story

Yahoo Finance • last month

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and g... Full story

Yahoo Finance • 2 months ago

Relay Therapeutics’ SWOT analysis: AI-driven biotech’s stock faces pivotal phase

Relay Therapeutics, Inc. (NASDAQ:RLAY), a biotechnology company specializing in precision medicine and AI-driven drug discovery, stands at a critical juncture in its development. With its lead candidate RLY-2608 progressing through clinica... Full story

Yahoo Finance • 2 months ago

Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates

Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase3ReDiscover-2trial in Q2 Approximately $657... Full story

Yahoo Finance • 2 months ago

Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025

CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental tec... Full story

Yahoo Finance • 4 months ago

Relay Therapeutics' SWOT analysis: AI-driven drug discovery stock faces pivotal phase

Relay Therapeutics, Inc. (NASDAQ:RLAY), a biotechnology company with a market capitalization of $552 million focused on AI-driven drug discovery, stands at a critical juncture in its development of RLY-2608, a mutant-selective PI3Ka inhibi... Full story

Yahoo Finance • 4 months ago

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental tec... Full story

Yahoo Finance • 4 months ago

Relay Therapeutics, Inc. (RLAY): A Bull Case Theory

We came across a bullish thesis on Relay Therapeutics, Inc. (RLAY) on Steve Wagner’s Substack. In this article, we will summarize the bulls’ thesis on RLAY. Relay Therapeutics, Inc. (RLAY)'s share was trading at $3.23 as of 4th June. A re... Full story

Yahoo Finance • 4 months ago

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation of pivotal study in... Full story

Yahoo Finance • 4 months ago

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental tech... Full story

Yahoo Finance • 5 months ago

Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates

Cash runway extended into 2029 Initiation of Phase3ReDiscover-2trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the Company meaningfully past... Full story

Yahoo Finance • 6 months ago

Is Relay Therapeutics Inc. (NASDAQ:RLAY) the Best Biotech Penny Stock to Buy According to Hedge Funds?

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Relay Therapeutics Inc. (NASDAQ:RLAY) stands against other biotech penny stocks. Peter... Full story

Yahoo Finance • 6 months ago

Barbara Weber, M.D., Elected to ITM Supervisory Board

Garching / Munich, Germany, April 09, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the election of Barbara Weber, M.D., to its Supervisory Board, effective May 01, 2025. Th... Full story

Yahoo Finance • 6 months ago

Relay Therapeutics (RLAY) Gets Analyst Boost as AI-Driven Drug Discovery Shines!

We recently published a list of Top 9 AI Ratings and News Updates on Wall Street’s Radar. In this article, we are going to take a look at where Relay Therapeutics Inc. (NASDAQ:RLAY) stands against other top AI ratings and news updates on W... Full story

Yahoo Finance • 8 months ago

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental tec... Full story

Yahoo Finance • 8 months ago

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025

CAMBRIDGE, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental tec... Full story

Yahoo Finance • 2 years ago

16 Most Promising Long-Term Stocks According to Analysts

In this piece, we will take a look at the 16 most promising long-term stocks according to analysts. If you want to skip our overview of long term investing, then you can take a look at 5 Most Promising Long-Term Stocks According to Analyst... Full story

Yahoo Finance • 2 years ago

Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) today announced that management will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023 at 1:5... Full story

Yahoo Finance • 2 years ago

Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights

Reported initial RLY-4008 (lirafugratinib) data demonstrating durable responses across multiple FGFR2-altered solid tumors Announced plans to initiate RLY-2608 + fulvestrant + CDK4/6 triplet combinations in HR+/HER2- breast cancer by YE 2... Full story

Yahoo Finance • 2 years ago

Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023

CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental tec... Full story